ONCY Stock Forecast: Oncolytics Biotech, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.35
−10.00% on the day

The median 12-month analyst price target for Oncolytics Biotech, Inc. is $4.98. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$53.1M
Ticker Nerd rank
38/ 100
Median analyst target
$4.98
Analysts covering
5
Revenue$0.0
Operating income−$9.4M
Net income−$9.4M
Free cash flow−$8.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−29.8%
YTD
−59.7%
1Y
−64.5%
From 52W high
−72.4%
From 52W low
+3.2%
$0.34
$1.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Oncolytics Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
38/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Volatility
74
Issuance
54
Value
50
Growth
42
Revisions
30
Momentum
17
Quality
12

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ONCY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ONCY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26ONCYHigh $5.82Median $4.98Low $2.83

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4
Buy
1
Hold
0
Sell
$2.83
Low
$4.98
Median
$5.82
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2026HC Wainwright & Co.ReiteratesBuy$5.00
19 Aug 2026HC Wainwright & Co.MaintainsBuy$10 → $5.00
26 May 2026HC Wainwright & Co.ReiteratesBuy—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
13 Aug 2025Lake StreetInitiatesBuy—
21 May 2025HC Wainwright & Co.ReiteratesBuy—
16 May 2025Jones TradingDowngradeHold—
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—
10 Mar 2025Maxim GroupMaintainsBuy—
10 Mar 2025RBC CapitalMaintainsOutperform—
3 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
19 Sept 2024HC Wainwright & Co.ReiteratesBuy—
21 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024Raymond JamesInitiatesOutperform—
8 Mar 2024HC Wainwright & Co.MaintainsBuy—
14 Feb 2024HC Wainwright & Co.ReiteratesBuy—
19 Jan 2024HC Wainwright & Co.ReiteratesBuy—
4 Jan 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ONCY.

Market Radar

This page is one stock. Monday covers all of them.

ONCY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ONCY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Oncolytics Biotech, Inc. returned −64.5% against +6.9% for the S&P 500, dividends included.

ONCY vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ONCYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ONCY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−211.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oncolytics Biotech, Inc. has a market value of $53.1M and an enterprise value of $43.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$38.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$26.7M.

  • Shares outstanding: 116.1M.

  • Oncolytics Biotech, Inc. employs 29 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

ONCY and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ONCYOncolytics Biotech, Inc.$53.1M38
CNXUConexeu Sciences, Inc.$47.8M1
HRTXHeron Therapeutics, Inc.$47.9M54
VRCAVerrica Pharmaceuticals, Inc.$47.1M49
IMAImageneBio, Inc.$48.8M33
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22
MISTMilestone Pharmaceuticals, Inc.$46.2M29

Take a look at ONCY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Oncolytics Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ONCY

What is the ONCY stock price forecast for 2026-2027?

The median 12-month analyst price target for Oncolytics Biotech, Inc. is $4.98, with estimates ranging from $2.83 to $5.82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ONCY stock a buy right now?

Of the 5 analysts covering Oncolytics Biotech, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oncolytics Biotech, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ONCY?

As at 21 Nov 2026, Oncolytics Biotech, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will ONCY stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $4.98, and Ticker Nerd's factor model ranks Oncolytics Biotech, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ONCY stock forecast for 2030?

No analyst covering Oncolytics Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ONCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.83 to $5.82 over the next 12 months.

How has ONCY stock performed over the past year?

Oncolytics Biotech, Inc. returned -64.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oncolytics Biotech, Inc. do?

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer. The company’s current programs center on solid tumors and hematological malignancies, with particular emphasis on gastrointestinal cancers such as colorectal, pancreatic, and anal cancers, as well as hormone receptor-positive, HER2-negative breast cancer.

Company

About Oncolytics Biotech, Inc.

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer. The company’s current programs center on solid tumors and hematological malignancies, with particular emphasis on gastrointestinal cancers such as colorectal, pancreatic, and anal cancers, as well as hormone receptor-positive, HER2-negative breast cancer. Its research approach combines pelareorep with chemotherapy and immune checkpoint inhibitors to improve how tumors respond to treatment. Oncolytics Biotech also advances clinical studies and regulatory development efforts through its pipeline and strategic collaborations, positioning the company within the oncology immunotherapy market.

CEO Mr. Jared Kelly J.D., L.L.M. · 29 employees · United States · https://oncolyticsbiotech.com